MedTrace Logo

Efficacy of IPL, an Anti-redness Dermocosmetic, and Their Combination in the Treatment of Rosacea

NCT07729540 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-07-27

No results posted yet for this study

Summary

This study compares three approaches to treating persistent facial redness in adults with erythematotelangiectatic rosacea: intense pulsed light (IPL) treatment alone, a professional anti-redness dermocosmetic skincare regimen alone, and the combination of both. The main question the study aims to answer is which of these three strategies is more effective at reducing facial redness, using both clinician grading and objective skin-imaging tools that measure redness and skin texture before and after treatment.

Conditions

  • Rosacea

Interventions

DEVICE

Intense Pulsed Light (IPL) - Lumecca

IPL treatment (515-1200 nm) delivered with the Lumecca applicator (InMode, Irvine, CA, USA), administered as three sessions at 21-day intervals with fluence individually titrated to skin response.

OTHER

Rosacure anti-redness dermocosmetic regimen

Professional in-office anti-redness regimen (Rosacure Professional system: gentle cleansing, Rosacure Professional Serum Booster, leave-on regenerating gel mask) plus a standardized 12-week home-care regimen (Rosacure Intensive SPF 30 mornings, Rosacure Fast evenings, leave-on mask twice weekly), manufactured by Synchroline/Cantabria Labs, Spain.

Sponsors & Collaborators

  • Synchroline/Cantabria Labs

    collaborator UNKNOWN

  • Medical University of Silesia

    lead OTHER

Principal Investigators

  • Anna Deda, PhD · Medical University of Silesia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
57 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-29
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07729540 on ClinicalTrials.gov